CagriSema produced an average 15.7% weight reduction in overweight or obese individuals with type 2 diabetes, according to ...

Novo Nordisk A/S (NYSE:NVO) announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...

Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...

New York, New York-- (Newsfile Corp. - March 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, ...

NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Shares of Danish obesity-drug maker Novo Nordisk, which provided clinical trial data from its CagriSema product that disappointed investors on Monday, continued their retreat, and are down about 11% ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity.

For the final quarter of 2024, the fund returned -5.12%, outpacing the -7.58% result of the benchmark MSCI All Country World ...

Eli Lilly's stock fell 4.58% following weak trial results from Novo Nordisk’s obesity drug, shaking investor confidence in ...